Introduction
Lymphoid tyrosine phosphatase (LYP) encoded by PTPN22 is an intracellular enzyme that dephosphorylates Src family kinases Lck and Fyn as well as components of the TCR/CD3 complex and other key signaling molecules. 1, 2 Therefore, LYP appears to be an important negative regulator of T-cell responses.
Recently, Bottini et al 3 described a single nucleotide polymorphism (SNP) in PTPN22 gene, 1858C4T, changing arginine to tryptophan residue in position 620 of mature protein. The 1858T (620W) variant was found associated with insulin-dependent diabetes mellitus. 3 Subsequently, association with 1858T was reproducibly described for other autoimmune diseases, including rheumatoid arthritis (RA). 2 Interestingly, a general view emerged that 1858T
variant is associated mostly with these autoimmune diseases, which exhibit a prominent contribution of autoantibodies. In contrast, association with 1858T could not be detected in autoimmune diseases where autoantibodies do not seem to play any role. 2 In RA, associations with 1858C4T were studied in several clinical manifestations, including a presence of rheumatoid factor (RF), anti-cyclic citrullinated peptide (aCCP) antibodies, erosive disease (ED), and extra-articular manifestations.
2,4 -8 However, a disease limited to joints vs RA with extra-articular complications was compared only in one study undertaken for a Spanish population, 7 which is genetically somewhat distant from Poles (eg, PTPN22 1858C4T frequencies are significantly different; Po0.0001 for difference in allele and genotype frequencies between Spaniards 7,9 and Poles (this report)). Therefore, we tested all clinical manifestations of RA mentioned above for distribution of 1858C4T SNP in Polish patients.
In autoimmune diseases, a harmful response to selfantigen(s) normally not invoking such reaction in healthy individuals is the etiological factor. Similarly, in allergic diseases, an exaggerated immune response to an 'innocent' antigen (allergen in this case) is observed. In addition, antibodies (of the IgE class) play important role in their pathogenesis, and several other effector pathways seem to contribute to both autoimmune and allergic pathology. 10 Thus, it seemed conceivable that PTPN22 polymorphism might play a role in allergic diseases as well. However, no such studies in allergy have been published so far. Therefore, in addition to the RA study, we compared here for the first time the distribution of 1858C4T alleles and genotypes in patients with allergic asthma and healthy control individuals.
Materials and methods

Study populations
A case -control association study was performed to examine whether the PTPN22 1858C4T missense (R620W) SNP was associated with different clinical manifestations of RA and allergic asthma.
One hundred and seventy-three patients (140 women and 33 men, age 57.9712.5 years, range 22 -83 years) with RA diagnosed as described by Pawlik et al, 11 12 and evidenced to be atopic as described. 13 The patients were subdivided according to NHLBI/WHO guidelines into three subgroups: asthma I, mild asthma (54 individuals); asthma II, moderate asthma (52 individuals); and asthma III, severe asthma (92 individuals). Characteristics of the patients are shown in Table 1b . Five hundred and forty-three unrelated healthy volunteers, ethnically matched, were considered for the control. Two hundred and thirty-three volunteers were recruited in Wrocław (mean age, 32.4710.7 years, range 14 -77 years; 103 women, 127 men, and 3 unknown). Three hundred and ten individuals were described elsewhere; 14 these persons (155 women and 155 men) were picked from paternity testing, and therefore their personal data, including age, must have been anonymous to obtain permission from the Local Ethical Committee. The project was approved by the Ethical Committees of the Pomeranian Medical University in Szczecin, Wrocław Medical University, and Medical University of Warsaw. Signed informed consent was obtained from all tested subjects, including parents in the case of juveniles.
DNA isolation and PTPN22 typing Genomic DNA was extracted from peripheral blood leukocytes using methods described earlier.
13 -15 PTPN22
1858C4T polymorphism was genotyped by RFLP-PCR using primers described by Bottini et al. 3 Two hundred and thirty-three control individuals from Wrocław and all patients were typed as follows: a fragment of PTPN22 gene was amplified by PCR in a 20 ml total volume reaction containing 200 ng genomic DNA, 2.5 mM MgCl 2 , 1 Â PCR buffer, 0.1 mM of each primer, 0.25 mM dNTPs, and 0.5 U Taq polymerase (Invitrogen). The amplifications were performed under the following conditions: 951C, 5 min; 30 cycles of 30 s at 951C, 30 s at 601C, and 30 s at 721C. The last elongation step was extended to 5 min. The PCR product was digested using 0.4 U XcmI restriction enzyme (New England BioLabs) for 4 h at 371C. All digested products were electrophoresed on 3% agarose. Three hundred and ten control individuals from Warsaw were typed in conditions as described. 3 
Statistical analysis
Frequencies of PTPN22 alleles were established by direct counting. Differences between controls, patients, and patient subgroups were estimated using two-tailed Fisher exact test and GraphPad InStat 3 software. For calculation of genotype frequencies, w 2 -test and EpiInfo software were used.
Results
RA patients differed from healthy control individuals in frequencies of PTPN22 1858C4T alleles (P ¼ 0.0004) and genotypes (P ¼ 0.0009), and the odds ratio (OR) for the T allele was 1.8 (Table 2 ). When we divided our patients according to the presence or absence of extra-articular complications, strong association of 1858T allele with a disease limited to joints (P ¼ 0.0002 and 0.0003 for alleles and genotypes, respectively) was observed (OR for T allele, 2.08). Patients with extra-articular manifestations, including vasculitis, did not differ from control group (Table 2 and data not shown). Genotype frequencies in all groups were found to be in the Hardy -Weinberg equilibrium (not shown).
Next, we looked for PTPN22 1858C4T association with RF. 1858T allele was only weakly associated (P ¼ 0.02) with seropositive RA but very strongly with seronegative RA (P ¼ 0.0008; OR ¼ 2.29; Table 2 ). Similarly, association of 1858C4T genotypes with seronegative RA was much stronger than with seropositive RA. 1858T-positive phenotype (TT homozygotes plus CT heterozygotes) was highly significantly more frequent in RF-negative patients than in controls (P ¼ 0.001), whereas its frequency in RF-positive patients was only weakly (P ¼ 0.02) different from controls.
The presence of aCCP antibodies in RA patients was very strongly associated with 1858T allele (Po0.0001) and 1858T carrier status (Po0.0001; Table 2 ).
We also checked whether 1858C4T SNP was associated with bone erosions in the joints (ED). Allele and genotype frequencies were highly significantly different from controls in patients with erosive disease (P ¼ 0.0003 and 0.0008, respectively) but not in patients without bone erosions (P40.05 for alleles, genotypes, and T phenotype; Table 2 ). Association of 1858T allele with erosive disease was much stronger in RF-negative patients (P ¼ 0.0008; OR, 2.5; 95% CI, 1.5 -4.3) than in RF-positive ones (P ¼ 0.02; OR, 1.6; 95% CI, 1.1 -2.5).
When patients with allergic asthma were typed for PTPN22 1858C4T polymorphism, no difference with control was found. Subdivision of patients into those with mild, moderate, or severe asthma did not reveal any associations (Table 3) .
Discussion
We describe here our results on associations of 1858C4T SNP with RA and allergic asthma. In RA, we confirm an association of 1858T allele with susceptibility to this disease, with OR (1.8) similar to that described by others (range, 1.4 -1.88). 5 -8,16,17 Moreover, a strong association of this SNP with erosive disease, described earlier in English population, 6 was also found in our patients. Much weaker association of 1858T with RA in patients without erosive disease, described by Hinks et al, 6 did not reach statistical significance in our study because our sample was small in comparison to theirs. We also found a strong association of 1858T allele with RA limited to joints, whereas patients with extra-articular manifestations did not reveal such Although multiple other SNPs were described in PTPN22 gene, most of them did not affect susceptibility to RA, with only one or two approaching the effect of 1858C4T. 16 It will be interesting, then, to check whether their associations can be reproduced in our sample. In the light of the strong contribution of 1858C4T SNP to RA and other autoimmune diseases, 2 we also expected to find its association with allergic asthma, for two reasons: (i) the effect of 1858T substitution on T-cell activity, which is exaggerated in allergy; and (ii) the involvement of antibodies (autoantibodies) to pathology of these autoimmune diseases, which exhibit 1858C4T associations, and also the involvement of antibodies (of IgE class) to pathology of allergy. To our surprise, 1858C4T allele and genotype frequencies were virtually identical in allergic asthmatic patients and controls. The explanation may be found in substantial differences between autoimmune and allergic diseases: although antibodies are involved in both types of disease, they differ both in immunoglobulin class and specificity (anti-self vs anti-allergen). In addition, even the association of 1858C4T SNP with autoantibodymediated diseases is not absolute; for example, systemic scleroderma, characterized by many autoantibodies, 24 is not associated with it. 25 In summary, we found strong associations of 1858C4T SNP with RA and its several clinical manifestations. We also performed, for the first time, a study on the distribution of 1858C4T in allergic asthma showing no association of this SNP with susceptibility to asthma or with its severity. 
